PPMP as a Ceramide Catabolism Inhibitor for Chemotherapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$249,947.00
Award Year:
2003
Program:
STTR
Phase:
Phase I
Contract:
1R41CA102842-01
Award Id:
65244
Agency Tracking Number:
CA102842
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
700 INDUSTRIAL PARK DR, 700 INDUSTRIAL PARK DR, Alabaster, AL, 35007
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
BARRY MAURER
(323) 669-5663
BMAURER@CHLA.USC.EDU
Business Contact:
(205) 663-2494
Research Institution:
CHILDREN'S HOSPITAL LOS ANGELES

4650 SUNSET BLVD
LOS ANGELES, CA, 90027

Domestic nonprofit research organization
Abstract
DESCRIPTION (provided by applicant): Our goal is to develop 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) as a clinical inhibitor of ceremide catabolism, in order to enhance the anti-cancer activity of the cytotoxic retinoid, fenretinide (4-HPR). We have reported that 4-HPR increased ceramide in numerous pediatric and adult solid cancer and leukemia cell lines in vitro. We have also reported that PPMP, an inhibitor of glucosylceramide synthase and l-O-acylceramide synthase, further increased ceramide and synergized 4-HPR cytotoxicity. We hypothesize that intravenous or oral formulations of PPMP can achieve plasma and tissue levels that inhibit ceramide catabolism in vitro. We hypothesize that PPMP will enhance the anti-cancer effect of 4-HPR with tolerable systemic toxicity in vivo. We will: AIM 1. Identify the stereoisomer of PPMP that most effectively inhibits ceramide catabolism and increases 4-HPR cytotoxicity. AIM 2. Develop a cGMP process, and produce PPMP for pre-IND studies. AIM 3. Formulate PPMP for intravenous and/or oral delivery. AIM 4. Perform small animal pharmacokinetic and toxicology studies to support a Phase II STTR application to support IND-directed toxicology studies and cGMP PPMP manufacture for Phase I clinical trial. 4-HPR+PPMP represents a novel, p53-independent chemotherapy that is based upon the generation and manipulation of ceramide in vivo.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government